Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...
Neurocrine Biosciences, Inc. announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in ...
Further expansion of the existing strategic partnership reflects continued high demand for Lonza’s high-quality global biologics outsourcing de...
Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, announced that it h...
Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company develo...
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), me...
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturin...
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise ...
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of He...
Complaint filed in San Diego County Superior Court seeks specific performance, alleging NRx warranted it had funds to close while concealing it lacked ...
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Biocom California, one of the world's largest ...
Araris Biotech AG, a company advancing a differentiated pipeline of antibody-drug conjugates (“ADCs”) therapies, and Taiho Oncology, Inc., a ...
New regional identity unites a more than $100 billion bioscience ecosystem and positions Indiana among the world's leading innovation hubs. BIO Internat...
Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals O...
© 2026 Biopharma Boardroom. All Rights Reserved.
